{"name":"PRG Science & Technology Co., Ltd.","slug":"prg-science-technology-co-ltd","ticker":"","exchange":"","domain":"prgsciencetechnology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Trineumin","genericName":"Trineumin","slug":"trineumin","indication":"Other","status":"phase_1"},{"name":"Amisodin","genericName":"Amisodin","slug":"amisodin","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Trineumin","genericName":"Trineumin","slug":"trineumin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amisodin","genericName":"Amisodin","slug":"amisodin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxQb1pMalVjYXMzcllqOEJYTnJROWFoUjMtaEdPVDNadU9yX1RvdWJZS1VEdnRvYmFrUjlBWEtvWHFjbDZWeWVRWFdtRHhSTFlxV3Y4UW5lODFtM2dselNIcFRaSmROTVUxTWF0R1lyVElFTHZsa3d2VmJOMjYtZUE4NTl1NWZ2SG9tRVRfaXVHOHdXUVlkcWVDTXMxYkdaTGJpQUVOWXI3M0N3bjRTZDBhVmdXLTRxdURvSzZlSjBSNk1TZWZPbjJEMzRRQXFSMkp3SFVrUG5iMFpKZVhhYTFRNEFCc1U3cTlpV1FxSkdNOWhIMFdGSlQ4ZWlnUWQzNXlsYVRuWGlKX3lkNDlZN2VQTlJldEFZbFM3dk9FUlBHc1hRcTA?oc=5","date":"2026-03-31","type":"pipeline","source":"Barchart.com","summary":"Hutchinson-Gilford Progeria Syndrome Market Outlook 2032: Orphan Drug Advancements and Pipeline Breakthroughs Expected to Fuel Growth, Reports DelveInsight - Barchart.com","headline":"Hutchinson-Gilford Progeria Syndrome Market Outlook 2032: Orphan Drug Advancements and Pipeline Breakthroughs Expected t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPUjA1UU1SaVRpWDZLcmtRRGFIeGIza3dFbTZEM1JPUTFQOFhfZmxJRnlYTE5YdlhCM0U3c1BYOXJIemRQOS1JeTR6Z1lSaHktWVkwRVN4aVhrVVFvWWVodXc5TXZ0cmlxS1ZJNXktbHdMcVBBSXl1bG5sZlRyRklhTndHZmtHZnVnLUpkbHNRdzZFcG1GNGxN?oc=5","date":"2026-03-31","type":"pipeline","source":"openPR.com","summary":"Hutchinson-Gilford Progeria Syndrome Market Outlook 2032: - openPR.com","headline":"Hutchinson-Gilford Progeria Syndrome Market Outlook 2032:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOb3JmT3JRT1AwVlJ6OWxLV28yV3pWVXdlNnpNV2FUMHM5eUFjREVlZEhtSzhycE9LNFB4aUhzT0VVZVlZV1VzZVFWOHMwYThmQWJ6emRPNHluUVNtLWo5YXlNdUlJSWtLazJRRGNUMFZ3U18tX3BZZ19wU2xCT2VUVHF5ck5uN2xEaGI1QUhXYzZPN0taRURNUEpqdjNadDdvOEZYNndaNWktNEJfNjFodDFoalpfUlhUMWVsYk85ams0TTB5anFMX2YyVVNDaDM3Mk5pZlFvb05Dd3BOWmFVTHRzVWRQRWhWQ1NrR0Q4WWVBSlY1eC1BbmNvWG1Pc3Jv?oc=5","date":"2026-03-16","type":"deal","source":"PR Newswire","summary":"Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome - PR Newswire","headline":"Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQNFlZeEJqNWd5Tng1Y1BHZFR3Rm1tLWl3REltOWctcjkzQWYxZ3JZb3VtbWJCWUVtZUVleThJdHcxRWtxeHUwQzNIUjUyZFFEajJRYzdRaGN6OG1iNGdUajlPYThxemNWSlk5aGwtY1FDOEdMaU10VjRNYWgtSnhxZnJ4UzhjWF80aWpOcGlqZDRXUEkzdEcyVEhoVUh3dUt1?oc=5","date":"2025-04-16","type":"pipeline","source":"openPR.com","summary":"Progeria Therapeutics Market Size in 7MM is expected to grow at - openPR.com","headline":"Progeria Therapeutics Market Size in 7MM is expected to grow at","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQamdGRHVKUDl0NVlUcHVMOUU3UEFWWV9OSUhVanhuSkpyS01fMERuM0MxVDdSZDBLR2dVMDk4UWZURXItWmh3LVpzMEV0MU1hNlNFSXJiVFNkM1JNZ1pKazNqeEkzZWw3Mm5MSGhadDRWemREYWJJaGxlZm5rLVFlWjRSQWthdlJlcmxEdUJJZ3pyTEdFbEFtWNIBlwFBVV95cUxPdGRBTXFnSElOdWhzSWFSOHRFYWNXZ0xTY3lHek1RdFd2QjE5S1VHclNiN3N0Tll6QkVONDRsNFdUYmhLOUQ4SFBWNExra21iZnVRdG5xNXBHaUczQ1QxSFpOWEJrQlFsVmhBcEhSS2pNZTN3b2RQU3BnblJIaW5mSWdDT2w2LTVlVnczRnJpZjhuTkNPSE1n?oc=5","date":"2025-02-27","type":"pipeline","source":"modernghana.com","summary":"Someone very powerful wants to flood Ghana with poisons – Bright Simons writes - modernghana.com","headline":"Someone very powerful wants to flood Ghana with poisons – Bright Simons writes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNcF84NE13YXNXLVJrb3NScTZRR0ttRldKZXQ5SmJQd0tBZldEM0lNYWtnZW9FN1N5ZjhJVno3LUdad2tmUS1ZZ2tLZmZ2QnJ5dmsyQ1owVEc3cG0yd0hIS0dHaTYxZmN4aVNVX2YzOUhEQXBJUVp0eDQteUlXVkZac3g2eS1HdThac2l3WW90LVJfbkI4Rk12dUpOUE5fbnlUTDk4VzJTSlk0bk9kZmZHTGFsbEsxdkszWC1PdGlpamtfTGNMZ0hNdE5aUTBjaFpNamZPV0Y0X0VlMXJWc0hBTjRKZ1BRbU5IcmtURkRjb0RwTmxqXzRUdzZ4Q1dmaVQ4aXc5TFJBTU9Nc1Y0UXA1OTNiVzJ3U1lBZDEyRGNrS2JGM0tQbmVodnJVNmM?oc=5","date":"2024-12-03","type":"trial","source":"PR Newswire","summary":"Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain - PR Newswire","headline":"Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOaUIzSWRtM1k0Ykp2QU5GeWhQUmxIbE9UdUxMdDRIV20tZmlfWTdYNmFJOEpIUEpFSGdBN3IyX1Q0ZUFQTDNPZXVTaG9uSHpBX09sUlpiYm9WNmtialljSmNZaW82X1FIN2ZoY09vZ3BsTWdsd0hDVXoyVWNJaGY0Rk9QQW1raUhYc2lDZ3dZMWhKc2tpb1V4VW1nR21SNlF2MVZRTEdmakhUSnVyVk1LUkZuLTNDUUNZeW1OS2t5TE5QMnNUWU9tVjh2SkNCTHYwUklZMnhsZXdoOWdsT2ticW13?oc=5","date":"2024-10-22","type":"pipeline","source":"PharmiWeb.com","summary":"Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics Market value of USD 233.05 Billion by regis - PharmiWeb.com","headline":"Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics Market value of USD 233.05 Billion by regis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNdlEwdXc2ejcySFh5QVFMUlpEeWZvQWhXRWhtOUt5RE14MnR3N0ljWHZzWk41M3VVb09nd2xYVXE1RkZ1MEpVbEVQTDZ5OUpZWElNbWYybEMtRzluWDNwZ0xXT25OM19HY09PVVhreWtrZngyVzJuZGN3ajFkVDZwMkY3R2xaMnhKLXNJRVhpRE85RGthVGpVd1l1SE9xUTBrOXVRR25fME1vNGNJVUwzcUxPOEh2SWFqRG1mYVVB?oc=5","date":"2024-10-02","type":"regulatory","source":"BioSpace","summary":"US FDA Authorizes Launch of Clinical Trial to Support New Treatment Development for Progeria - BioSpace","headline":"US FDA Authorizes Launch of Clinical Trial to Support New Treatment Development for Progeria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPcVlVTjdWX0RGaWlKbEZhdXpoaFJybGZ6TW1yR09DR2ZIUHphd1N0S0VMUzFPSDRnWVFscGhud1ZhSnpRNi1WbHhvU0FHbTB1cWp0TDFUUjFvMUJsRzdLMG1fcl9tVnpRMzB5M3k1Mmxqd2R4SmUxSDlXZUhHSHp3UE1fVGRLWENzYVdDUVVxbGpFQQ?oc=5","date":"2024-04-16","type":"pipeline","source":"Cleanroom Technology","summary":"TRU Cleanroom Cleaning changes name to venture into the US - Cleanroom Technology","headline":"TRU Cleanroom Cleaning changes name to venture into the US","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":8,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}